Hoth used the option period to evaluate GW's unique Substance P receptor blocker (Aprepitant) that inhibited cutaneous and other neurogenic inflammation side effects that cancer patients suffer during treatment with anticancer drugs. The exercise of the option agreement allows for Hoth to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, so Hoth anticipates finalizing the license this month.
In June of 2019, Hoth entered into a sponsored research agreement with GW to explore the potential use of Aprepitant in different forms.
Mr.
About
Forward Looking Statements
This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the BioLexa Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as 'anticipate', 'being', 'will', 'plan', 'may', 'continue', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Hoth's current expectations and various assumptions. Hoth believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described under the caption 'Risk Factors' in Hoth's Form 10K for the period ending
Contact:
Tel: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
Web: www.hoththerapeutics.com
(C) 2020 Electronic News Publishing, source